Casi Pharmaceuticals Stock Analysis

CASI Stock Analysis Notes

About 63.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.02. CASI Pharmaceuticals had not issued any dividends in recent years. The entity had 1:10 split on the 2nd of June 2022. CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland. Casi Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 176 people. For more info on CASI Pharmaceuticals please contact RPh MBA at 86 10 6508 6063 or go to https://www.casipharmaceuticals.com.

CASI Pharmaceuticals Investment Alerts

CASI Largest EPS Surprises

View All Earnings Estimates

CASI Stock Institutional Investors

Note, although CASI Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

CASI Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.34 M.

CASI Profitablity

The company has Profit Margin (PM) of (1.84) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.33) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.33.

Management Efficiency

CASI Pharmaceuticals has return on total asset (ROA) of (0.618) % which means that it has lost $0.618 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.945) %, meaning that it created substantial loss on money invested by shareholders. CASI Pharmaceuticals' management efficiency ratios could be used to measure how well CASI Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.69. The CASI Pharmaceuticals' current Return On Capital Employed is estimated to increase to -1.97. As of now, CASI Pharmaceuticals' Non Currrent Assets Other are increasing as compared to previous years. The CASI Pharmaceuticals' current Debt To Assets is estimated to increase to 0.39, while Total Assets are projected to decrease to under 49.2 M.

Technical Drivers

As of the 5th of February, CASI Pharmaceuticals shows the Mean Deviation of 3.72, variance of 27.99, and Market Risk Adjusted Performance of (0.31). CASI Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the entity's future prices.

CASI Pharmaceuticals Price Movement Analysis

CASI Pharmaceuticals Insider Trading Activities

CASI Pharmaceuticals Outstanding Bonds

CASI Pharmaceuticals Predictive Daily Indicators

CASI Pharmaceuticals Forecast Models

CASI Pharmaceuticals' time-series forecasting models are one of many CASI Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary CASI Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

CASI Pharmaceuticals Debt to Cash Allocation

CASI Pharmaceuticals currently holds 22.14 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. CASI Pharmaceuticals has a current ratio of 3.15, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about CASI Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

CASI Pharmaceuticals Common Stock Shares Outstanding Over Time

CASI Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which CASI Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

CASI Pharmaceuticals Debt Ratio

39.0

It feels like under 61% of CASI Pharmaceuticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the CASI Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of CASI Pharmaceuticals, which in turn will lower the firm's financial flexibility.

CASI Pharmaceuticals Corporate Bonds Issued

CASI Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how CASI Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling CASI shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as CASI Pharmaceuticals. By using and applying CASI Stock analysis, traders can create a robust methodology for identifying CASI entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CASI analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. CASI analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

CASI Pharmaceuticals stock analysis indicators help investors evaluate how CASI Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading CASI Pharmaceuticals shares will generate the highest return on investment. By understating and applying CASI Pharmaceuticals stock analysis, traders can identify CASI Pharmaceuticals position entry and exit signals to maximize returns.

When running CASI Pharmaceuticals' price analysis, check to measure CASI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CASI Pharmaceuticals is operating at the current time. Most of CASI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of CASI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CASI Pharmaceuticals' price. Additionally, you may evaluate how the addition of CASI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.